Edvan Q Crusoé

9PUBLICATIONS
73CO-AUTHORS
Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyHaematological tumoursRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Aug 27, 2026
Real-world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara-VTd) induction and lenalidomide maintenance in transplant-eligible multiple myeloma.

|May 12, 2026
Daratumumab-bortezomib-cyclophosphamide-dexamethasone for newly diagnosed amyloidosis: ANDROMEDA final survival analysis.

|Dec 06, 2025
Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis.

João Tadeu Damian Souto Filho, Lucas Oliveira Cantadori, Edvan de Queiroz Crusoe

|Aug 19, 2025
Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis.

Andrew Spencer, Maria Gavriatopoulou, Daniel Coriu

|May 07, 2025
Challenges in the integration of palliative care for patients with hematologic malignancies: an analysis of the surprise question in a prospective cohort study.

Alini Maria Orathes Ponte Silva, Diego Lopes Paim Miranda, David Pereira Ferreira

|Mar 14, 2025
Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis.

João Tadeu Damian Souto Filho, Lucas Oliveira Cantadori, Edvan de Queiroz Crusoe

Pageof 2

Frequent Collaborators

5 joint publications

Vania Hungria

3 joint publications

João Tadeu Damian Souto Filho

3 joint publications

Angelo Maiolino

2 joint publications

Alini Maria Orathes Ponte Silva